These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27624569)

  • 1. Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.
    Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Blanco JL; Mosquera MM; Peñafiel J; Gatell JM; Marcos MA; Miró JM
    J Antimicrob Chemother; 2017 Jan; 72(1):205-209. PubMed ID: 27624569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
    Ambrosioni J; Rico JÁF; Nicolás D; Mosquera MM; de Lazzari E; Marcos MÁ; García F; Miró JM;
    AIDS; 2019 Aug; 33(10):1613-1617. PubMed ID: 31090546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary resistance to integrase strand-transfer inhibitors in Europe.
    Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
    J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
    Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
    HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
    Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
    Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
    Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.
    Armenia D; Fabeni L; Alteri C; Di Pinto D; Di Carlo D; Bertoli A; Gori C; Carta S; Fedele V; Forbici F; D'Arrigo R; Svicher V; Berno G; Pizzi D; Nicastri E; Sarmati L; Pinnetti C; Ammassari A; D'Offizi G; Latini A; Andreoni M; Antinori A; Ceccherini-Silberstein F; Perno CF; Santoro MM
    J Antimicrob Chemother; 2015; 70(6):1865-73. PubMed ID: 25712318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
    Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
    De Francesco MA; Izzo I; Properzi M; Gargiulo F; Caccuri F; Quiros-Roldan E; Castelli F; Caruso A; Focà E
    AIDS Res Hum Retroviruses; 2018 Jul; 34(7):570-574. PubMed ID: 29631420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
    J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
    Nguyen T; Fofana DB; Lê MP; Charpentier C; Peytavin G; Wirden M; Lambert-Niclot S; Desire N; Grude M; Morand-Joubert L; Flandre P; Katlama C; Descamps D; Calvez V; Todesco E; Marcelin AG
    J Antimicrob Chemother; 2018 Sep; 73(9):2485-2492. PubMed ID: 29873733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.